Study details
Enrolling now
Glecaprevir/Pibrentasvir Trial for PTSD
White River Junction Veterans Affairs Medical Center
NCT IDNCT05637879ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2/3
Target enrollment
92
Study length
about 2.8 years
Ages
19–70
Locations
1 site in VT
What this study is about
Researchers are testing glecaprevir/pibrentasvir, a medication, to see if it helps with Post-traumatic Stress Disorder (PTSD). The trial will last 1017 days and involve approximately 92 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Take Glecaprevir/pibrentasvir
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
Antiviral Agent [TC] (Breast Cancer Resistance Protein Inhibitors)
Body systems
Psychiatry / Mental Health